Shilpa Medicare Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Shilpa Medicare Ltd is ₹ 477 as of 18 May 15:30 . The P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 21.1 on March 2021 to 19.7 on March 2025 . This represents a CAGR of -1.36% over 5 years The Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 45131 crore on March 2021 to ₹ 89122 crore on March 2025 . This represents a CAGR of 14.58% over 5 years The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The revenue of Zydus Lifesciences Ltd for the Dec '25 is ₹ 6975 crore as compare to the Sep '25 revenue of ₹ 6232 crore. This represent the growth of 11.93% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The ebitda of Zydus Lifesciences Ltd for the Dec '25 is ₹ 1842 crore as compare to the Sep '25 ebitda of ₹ 2090 crore. This represent the decline of -11.85% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 965.1 crore over 7 quarters. This represents a CAGR of -21.18% The Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 24.28 % on March 2021 to 19.16 % on March 2025 . This represents a CAGR of -4.63% over 5 years .

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Shilpa Medicare Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Shilpa Medicare Ltd or Zydus Lifesciences Ltd?

Market cap of Shilpa Medicare Ltd is 9,329 Cr while Market cap of Zydus Lifesciences Ltd is 99,737 Cr

What are the key factors driving the stock performance of Shilpa Medicare Ltd and Zydus Lifesciences Ltd?

The stock performance of Shilpa Medicare Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Shilpa Medicare Ltd and Zydus Lifesciences Ltd?

As of May 18, 2026, the Shilpa Medicare Ltd stock price is INR ₹477.0. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹991.2.

How do dividend payouts of Shilpa Medicare Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Shilpa Medicare Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.